University of Minnesota
Achieving sustained blood levels of carbidopa/levodopa has been a challenge in the treatment of PD and although levodopa remains the most commonly used drug, motor fluctuations remain a major disability especially in advanced Parkinson's disease. The aim of this study is to determine the efficacy of a novel oral carbidopa-levodopa formulation in achieving a sustained blood level of levodopa and carbidopa in normal volunteers.
Healthy Volunteers
levodopa/carbidopa oral formulation A
levodopa/carbidopa oral formulation B
EARLY_PHASE1
| Study Type : | INTERVENTIONAL |
| Estimated Enrollment : | 6 participants |
| Masking : | DOUBLE |
| Masking Description : | Double-blinded |
| Primary Purpose : | TREATMENT |
| Official Title : | Sustained Release Oral Formulation for Treatment of Parkinson's Disease |
| Actual Study Start Date : | 2025-06-12 |
| Estimated Primary Completion Date : | 2026-06-16 |
| Estimated Study Completion Date : | 2026-06-16 |
Information not available for Arms and Intervention/treatment
| Ages Eligible for Study: | 18 Years to 65 Years |
| Sexes Eligible for Study: | ALL |
| Accepts Healthy Volunteers: | 1 |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
RECRUITING
University of Minnesota
Minneapolis, Minnesota, United States, 55455